+ Community
Kacie Whaley | Sep 1, 2017

Rare disease therapy company, Shire, making executive changes

Shire, a company that develops innovative therapies for rare diseases, will be undergoing changes in its executive ranks.  

The company's chief financial officer, Jeff Poulton, will be stepping down at the end of the year, Shire said in a release. During the transition, he will continue to sit on the executive committee and the board of directors as well as remain involved in the company's strategic review.

“It is with regret that we announce Jeff’s upcoming departure," Shire CEO Flemming Ornskov said in the release. "Having held numerous roles within the company, Jeff has demonstrated steadfast commitment to Shire through a very intense period of activity and has made significant contributions to our organization. Jeff will continue to lead the Shire finance team through the Q3 reporting period and to the end of the year, and (he) will play an active role in the search for his successor. On behalf of all Shire employees, we are grateful to Jeff for his dedication and leadership and wish him the very best in his future endeavors.”

Poulton is leaving Shire to become the chief financial officer at Indigo Ag Inc., a startup company that utilizes microbiome to improve agriculture.

“It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company," Poulton said in the release. "It has been a difficult decision, but in departing Shire, I wanted to join a smaller organization where I can play a role in building a new company."

Shire also said that Joanne Cordeiro, interim head of human resources since March, has been appointed chief human resources officer and a member of the executive committee. 

Organizations in this story

+ Shire

More News